Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381366 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study
A Phase 1 study, sponsored by Medipost.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02381366 is a Phase 1 study that has completed, run by Medipost. The registered enrollment target is 12 participants.
The verdict
NCT02381366, a Phase 1 study, has completed, sponsored by Medipost.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
PNEUMOSTEM® consists of ex vivo cultured allogeneic, unrelated, human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and it is intended for use as a cellular therapy product for prevention of Bronchopulmonary Dysplasia (BPD). This study is an open-label, single-center, dose escalation study to evaluate of safety and efficacy of PNEUMOSTEM® in premature infants at high risk for BPD.
Interventions
- BIOLOGICAL Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02381366
The ClinicalTrials.gov registry entry for NCT02381366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medipost, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells is the first listed.
NCT02381366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02381366 about?
NCT02381366 is a clinical study titled "Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study". PNEUMOSTEM® consists of ex vivo cultured allogeneic, unrelated, human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and it is intended for use as a cellular therapy product for prevention of Bronchopulmonary Dysplasia (BPD). This study is an open-label, single-center, dose escalati...
What is the current status of trial NCT02381366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02381366?
The interventions under investigation include: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02381366?
This trial is sponsored by Medipost, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.